Trial
NCT03094195
Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Post-herpetic Neuralgia
Intervention
EMA401
Why stopped
The study was terminated early due to pre-clinical toxicity data that became available after start of trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-08